Ralph S. Baric

University of North Carolina (UNC) at Chapel Hill - Department of Microbiology and Immunology

SCHOLARLY PAPERS

4

DOWNLOADS

136

TOTAL CITATIONS

2

Scholarly Papers (4)

1.

Outcomes of Convalescent Plasma with Defined High- Versus Lower-Neutralizing Antibody Titers Against SARS-CoV-2 Among Hospitalized Patients: Coronavirus Inactivating Plasma (CoVIP), Double-Blind Phase 2 Study

Number of pages: 32 Posted: 25 Apr 2022
University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases, University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases, University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases, University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases, University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases, University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases, University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases, University of North Carolina (UNC) at Chapel Hill - UNC HIV Cure Center, University of North Carolina (UNC) at Chapel Hill - Department of Microbiology and Immunology, University of North Carolina (UNC) at Chapel Hill - Department of Epidemiology, University of North Carolina School of Medicine - Department of Microbiology and Immunology, University of North Carolina (UNC) at Chapel Hill, University of North Carolina (UNC) at Chapel Hill - Department of Microbiology and Immunology, University of North Carolina (UNC) at Chapel Hill, University of North Carolina (UNC) at Chapel Hill, University of North Carolina (UNC) at Chapel Hill - Department of Microbiology and Immunology, University of North Carolina School of Medicine - Department of Microbiology and Immunology, University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases, University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases, University of North Carolina (UNC) at Chapel Hill - Institute for Global Health and Infectious Diseases and The University of North Carolina at Chapel Hill - UNC HIV Cure Center
Downloads 53 (838,318)

Abstract:

Loading...

Antibodies, SARS-CoV-2, Convalescent Plasma, Immunology, neutralizing antibodies

2.

Genomic RNA Elements Drive Phase Separation of the SARS-CoV-2 Nucleocapsid

Number of pages: 45 Posted: 31 Jul 2020
University of North Carolina (UNC) at Chapel Hill - Department of Biology, University of North Carolina (UNC) at Chapel Hill - Department of Biology, University of North Carolina (UNC) at Chapel Hill - Department of Chemistry, Flatiron Institute - Center for Computational Biology, University of North Carolina (UNC) at Chapel Hill - Department of Biology, Massachusetts Institute of Technology and Harvard University - Broad Institute, Flatiron Institute, Princeton University - Department of Computer Science, University of North Carolina (UNC) at Chapel Hill - Department of Microbiology and Immunology, University of North Carolina (UNC) at Chapel Hill - Department of Epidemiology, Princeton University - Lewis-Sigler Institute for Integrative Genomics, Princeton University - Lewis-Sigler Institute for Integrative Genomics, University of North Carolina (UNC) at Chapel Hill - Department of Microbiology and Immunology, University of North Carolina (UNC) at Chapel Hill - Department of Epidemiology, University of North Carolina (UNC) at Chapel Hill - Department of Chemistry and University of North Carolina (UNC) at Chapel Hill - Department of Biology
Downloads 42 (923,370)
Citation 1

Abstract:

Loading...

3.

SARS-CoV-2 mRNA Vaccine Induces Robust Specific and Cross-Reactive IgG and Unequal Strain-Specific Neutralizing Antibodies in Naïve and Previously Infected Recipients

Number of pages: 34 Posted: 02 Jul 2021
University of North Carolina School of Medicine - Department of Microbiology and Immunology, George Washington University - Department of Emergency Medicine, University of North Carolina School of Medicine - Department of Microbiology and Immunology, George Washington University - Department of Emergency Medicine, University of North Carolina (UNC) at Chapel Hill - Department of Family Medicine, University of North Carolina School of Medicine - Department of Microbiology and Immunology, University of North Carolina School of Medicine - Department of Microbiology and Immunology, University of North Carolina (UNC) at Chapel Hill - Department of Microbiology and Immunology, George Washington University - Department of Emergency Medicine and University of North Carolina School of Medicine - Department of Microbiology and Immunology
Downloads 21 (1,154,574)
Citation 1

Abstract:

Loading...

antibody response; vaccine induced immunity; neutralization; SARS-CoV-2 variants; human endemic coronavirus; serostatus determination

4.

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

Number of pages: 59 Posted: 18 Feb 2022
Duke University - Duke Human Vaccine Institute, University of North Carolina (UNC) at Chapel Hill - Department of Epidemiology, University of North Carolina (UNC) at Chapel Hill - Department of Epidemiology, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Department of Surgery, Duke University - Duke Human Vaccine Institute, Duke University - Department of Surgery, Government of the United States of America - Infectious Disease Pathogenesis Section, Comparative Medicine Branch, Government of the United States of America - Infectious Disease Pathogenesis Section, Comparative Medicine Branch, Government of the United States of America - Infectious Disease Pathogenesis Section, Comparative Medicine Branch, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Duke University - Department of Surgery, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration - Division of Viral Products, Duke University - Duke Human Vaccine Institute, Beth Israel Deaconess Medical Center, University of Pennsylvania - Department of Microbiology, University of Pennsylvania - Department of Microbiology, Corporate Research Materials Lab, 3M Company, Infectious Disease Research Institute, Government of the United States of America - Infectious Disease Pathogenesis Section, Comparative Medicine Branch, BIOQUAL, BIOQUAL, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration - Division of Viral Products, Government of the United States of America - Vaccine Research Center, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration - Division of Viral Products, University of North Carolina (UNC) at Chapel Hill - Department of Microbiology and Immunology, Duke University - Duke Human Vaccine Institute, Duke University - Duke Human Vaccine Institute and Duke University - Duke Human Vaccine Institute
Downloads 20 (1,167,001)

Abstract:

Loading...